贝伐珠单抗联合FOLFIRI方案治疗晚期直肠癌并发直肠阴道瘘1例报告及文献复习

doi:10.13481/j.1671-587X.20220329

吉林大学学报(医学版) ›› 2022, Vol. 48 ›› Issue (3): 790-795.doi: 10.13481/j.1671-587X.20220329

贝伐珠单抗联合FOLFIRI方案治疗晚期直肠癌并发直肠阴道瘘1例报告及文献复习

侯俊杰^1,²,米旭光¹,李晓男¹,李孝男¹,杨影¹,江显卓¹,周颖¹,倪志强¹,金宁一^2,³,方艳秋¹()

^1.吉林省人民医院肿瘤综合治疗科，吉林长春 130021
^2.延边大学医学院病理生理学教研室，吉林延吉133002
^3.军事医学科学院分子病毒学与免疫学实验室，吉林长春 130122

收稿日期:2021-08-26 出版日期:2022-05-28 发布日期:2022-06-21
通讯作者: 方艳秋 E-mail:yq.fang@163.com
作者简介:侯俊杰（1979－），男，吉林省长春市人，副主任医师，在读博士研究生，主要从事肿瘤诊断和综合治疗方面的研究。
基金资助:
吉林省卫健委卫生与健康科技创新项目(2020J109)

Treatment of advanced rectal cancer with rectovaginal fistula through bevacizumab combined with FOLFIRI regimen: A case report and literature review

Junjie HOU^1,²,Xuguang MI¹,Xiaonan LI¹,Xiaonan LI¹,Ying YANG¹,Xianzhuo JIANG¹,Ying ZHOU¹,Zhiqiang NI¹,Ningyi JIN^2,³,Yanqiu FANG¹()

^1.Department of Comprehensive Oncology，People’s Hospital，Jilin Province，Changchun 130021，China
^2.Department of Physiopathology，School of Medical Sciences，Yanbian University，Yanji 133002，China
^3.Laboratory of Molecular Virology and Immunology，Institute of Military Veterinary Medicine，Academy of Military Medical Science，Changchun 130122，China

Received:2021-08-26 Online:2022-05-28 Published:2022-06-21
Contact: Yanqiu FANG E-mail:yq.fang@163.com

摘要/Abstract

摘要： 目的

探讨贝伐珠单抗联合化疗治疗已形成直肠阴道瘘直肠癌患者的疗效，为该病的治疗提供参考依据。

方法

收集1例采用贝伐珠单抗联合FOLFIRI方案治疗的晚期直肠癌伴直肠阴道瘘患者的临床资料，分析其诊治特点和过程，并对相关文献进行总结。

结果

患者，女性，64岁，于吉林省人民医院行经腹直肠癌手术（Dioxon手术），术后病理为中分化直肠腺癌，阴道后壁侵犯及区域淋巴结转移（pT4bN2M0，ⅢC期，Dukes C）；免疫组织化学检测，MSH2（+）、MLH1（+）、PMS2（+）、MSH6（+）、S-100（－）和BRAFV600E（－），提示错配修复蛋白功能正常（pMMR）；该患者发生N-和K-ras基因突变，术后4周辅助化疗前盆腔核磁成像（MRI）显示术后直肠阴道瘘，延期化疗，术后5个月疾病继续进展，被迫行姑息性一线、二线化疗，但疾病持续进展，三线采用贝伐珠单抗联合FOLFIRI方案治疗，未加重直肠阴道瘘，且促进了瘘道愈合，并显著提高了患者的生活质量。

结论

针对肿瘤进展导致直肠阴道瘘且无法从西妥昔单抗治疗中受益的直肠癌患者，采用贝伐珠单抗联合化疗进行针对病因的治疗是一种可行的方案。

关键词: 直肠肿瘤, 贝伐珠单抗, 辅助化疗, 直肠阴道瘘, 临床部分缓解, 病例报告

Abstract: Objective

To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of the rectal cancer patients with rectovaginal fistula，and to provide the reference basis for the treatment of the disease.

Methods

The clinical data of one patient with advanced rectal cancer with rectovaginal fistula treated with bevacizumab combined with FOLFIRI were collected，and the characteristics and process of diagnosis and treatment were analyzed； the relevant literatures were summarized at the same time.

Results

A 64-year-old female patient received transabdominal rectal cancer surgery （Dixon surgery） in People’s Hospital of Jilin Province，and the postoperative pathological results showed moderately differentiated rectal adenocarcinoma，invasion of posterior wall of vagina and regional lymph node metastasis （pT4bN2M0， Stage ⅢC，Dukes C）；the immunohistochemistry results showed MHS2（+），MLH1（+），PMS2（+），MSH6（+），S-100（－），and BRAFV600E（－），indicating proficiency of mismatch repair（pMMR）；the patient had N- and K-RAS gene mutations.The pelvic MRI results at 4 weeks after surgery revealed the postoperative rectovaginal fistula before pre-adjuvant chemotherapy.The chemotherapy was postponed， and the disease continued to progress 5 months after surgery， and the palliative first-line and second-line chemotherapy were perfermed under compulsion.However， the disease continued to progress， and the third-line chemotherapy of bevalizumab combined with FOLFIRI regimen was performed and did not aggravate the rectovaginal fistula， and promoted the fistula healing，while significantly improved the quality of life of the patient.

Conclusion

Bevacizumab combined with chemotherapy is a feasible treatment option for the rectal cancer patients with rectovaginal fistula caused by the tumor progression and will not benefit from the cetuximab therapy.

Key words: Rectal neoplasm, Bevacizumab, Adjuvant chemotherapy, Rectovaginal fistula, Clinical partial response, Case report

中图分类号:

R730.6

侯俊杰,米旭光,李晓男,李孝男,杨影,江显卓,周颖,倪志强,金宁一,方艳秋. 贝伐珠单抗联合FOLFIRI方案治疗晚期直肠癌并发直肠阴道瘘1例报告及文献复习[J]. 吉林大学学报(医学版), 2022, 48(3): 790-795.

Junjie HOU,Xuguang MI,Xiaonan LI,Xiaonan LI,Ying YANG,Xianzhuo JIANG,Ying ZHOU,Zhiqiang NI,Ningyi JIN,Yanqiu FANG. Treatment of advanced rectal cancer with rectovaginal fistula through bevacizumab combined with FOLFIRI regimen: A case report and literature review[J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 790-795.

图/表 4

参考文献 23

1	CERCEK A， ROXBURGH C S D， STROMBOM P， et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer［J］. JAMA Oncol， 2018， 4（6）： e180071.
2	LEE J H， LEE J H， AHN J H， et al. Randomized trial of postoperative adjuvant therapy in stage Ⅱ and Ⅲ rectal cancer to define the optimal sequence of chemotherapy and radiotherapy： a preliminary report［J］. J Clin Oncol， 2002， 20（7）： 1751-1758.
3	FELIU J， SALUD A， SAFONT M J， et al. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC： GEMCAD phase Ⅱ BECOX study［J］. Br J Cancer， 2014， 111（2）： 241-248.
4	TEBBUTT N C， WILSON K， GEBSKI V J， et al. Capecitabine， bevacizumab， and mitomycin in first-line treatment of metastatic colorectal cancer： results of the Australasian Gastrointestinal Trials Group Randomized Phase Ⅲ MAX Study［J］. J Clin Oncol， 2010， 28（19）： 3191-3198.
5	CUNNINGHAM D， LANG I， MARCUELLO E，et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer （AVEX）： an open-label， randomised phase 3 trial［J］. Lancet Oncol，2013，14（11）：1077-1085.
6	GARCIA J， HURWITZ H I， SANDLER A B， et al. Bevacizumab （Avastin®） in cancer treatment： a review of 15 years of clinical experience and future outlook［J］. Cancer Treat Rev， 2020， 86： 102017.
7	徐圣君，赵晓平. 胸腺法新联合抗生素用于恶性肿瘤并发肺部感染的疗效观察［J］. 中国肿瘤临床与康复， 2019， 26（9）： 1073-1076.
8	KOSUGI C， SAITO N， KIMATA Y， et al. Rectovaginal fistulas after rectal cancer surgery： incidence and operative repair by gluteal-fold flap repair［J］. Surgery， 2005， 137（3）： 329-336.
9	NAKAGOE T， SAWAI T， TUJI T， et al. Successful transvaginal repair of a rectovaginal fistula developing after double-stapled anastomosis in low anterior resection： report of four cases［J］.Surg Today， 1999，29（5）： 443-445.
10	YUAN F， CHEN Y， DELLIAN M， et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody［J］. Proc Natl Acad Sci U S A， 1996， 93（25）： 14765-14770.
11	BATCHELOR T T， SORENSEN A G， DI TOMASO E， et al. AZD2171， a pan-VEGF receptor tyrosine kinase inhibitor， normalizes tumor vasculature and alleviates edema in glioblastoma patients［J］. Cancer Cell， 2007， 11（1）： 83-95.
12	JAIN R K. Normalization of tumor vasculature： an emerging concept in antiangiogenic therapy［J］. Science， 2005， 307（5706）： 58-62.
13	TURLEY R S， FONTANELLA A N， PADUSSIS J C，et al. Bevacizumab-induced alterations in vascular permeability and drug delivery： a novel approach to augment regional chemotherapy for in-transit melanoma［J］.Clin Cancer Res，2012，18（12）：3328-3339.
14	SETO T， KATO T， NISHIO M， et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations （JO25567）： an open-label， randomised， multicentre， phase 2 study［J］. Lancet Oncol， 2014， 15（11）： 1236-1244.
15	HURWITZ H I， FEHRENBACHER L， HAINSWORTH J D， et al. Bevacizumab in combination with fluorouracil and leucovorin： an active regimen for first-line metastatic colorectal cancer［J］. J Clin Oncol， 2005， 23（15）： 3502-3508.
16	BENNOUNA J， SASTRE J， ARNOLD D， et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer （ML18147）： a randomised phase 3 trial［J］. Lancet Oncol， 2013， 14（1）： 29-37.
17	EMMANOUILIDES C， SFAKIOTAKI G， ANDROULAKIS N， et al. Front-line bevacizumab in combination with oxaliplatin， leucovorin and 5-fluorouracil （FOLFOX） in patients with metastatic colorectal cancer： a multicenter phase Ⅱ study［J］. BMC Cancer， 2007， 7： 91.
18	DOUILLARD J Y， SIENA S， CASSIDY J， et al. Randomized， phase III trial of panitumumab with infusional fluorouracil， leucovorin， and oxaliplatin （FOLFOX4） versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer： the PRIME study［J］. J Clin Oncol， 2010， 28（31）： 4697-4705.
19	BENSON A B， VENOOK A P， AL-HAWARY M M， et al. Rectal cancer， version 2.2018， NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw， 2018， 16（7）： 874-901.
20	GORDON M S， CUNNINGHAM D. Managing patients treated with bevacizumab combination therapy［J］. Oncology， 2005， 69（）： 25-33.
21	CHÉREAU E， STEFANESCU D， SELLE F， et al. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer： a case report［J］. Am J Obstet Gynecol， 2009， 200（1）： e15-e16.
22	LEY E J， VUKASIN P， KAISER A M， et al. Delayed rectovaginal fistula： a potential complication of bevacizumab （avastin）［J］.Dis Colon Rectum，2007，50（6）： 930.
23	GALANOPOULOS M， LADIAS S， TZANNETAKOU X，et al. A rectovaginal fistula after treatment with bevacizumab. A dangerous side effect needing emergency treatment［J］. Clin Case Rep， 2016， 4（4）： 449-450.

[1]	石芯宁,张琦,张晗,李欣鹏,常路广达,吴雨颀,朱宪春. 无托槽隐形矫治安氏Ⅱ类1分类替牙列期患儿1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(3): 828-835.
[2]	周中伟,杜伟,宁宇,于晶,郭峰有,杨学良. SMARCB1/INI1缺失型未分化胰腺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(2): 523-529.
[3]	丁艺,贾文慧,杨晨露,董春玲. 呈黄褐混浊态的双侧胸腔积液快速交替进展患者1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(2): 530-535.
[4]	田磊, 刘宇妍, 王雨晴, 张芷钰, 孙秀梅. 单颌拔牙矫治Ⅲ°开并发舌体肥大1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(1): 236-245.
[5]	李双季,时赫,秦一文,李想,李裕洋,刘炜炜,李佳. 下颌骨促纤维结缔组织增生性纤维瘤1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(1): 246-251.
[6]	孙磊,于泳,刘晓军,苗盛. 染色体核型46，XX男性性反转综合征1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(1): 252-256.
[7]	刘艺,孟庆广,胡格吉勒null,曲扬. 脊柱痛风累及椎间盘致神经压迫患者行单侧双通道内镜手术治疗1例报告及文献复习[J]. 吉林大学学报(医学版), 2026, 52(1): 257-263.
[8]	敖倩,李婧婷,梁楠,孙辉. 青少年DICER1突变阳性的复发性滤泡亚型甲状腺乳头状癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2025, 51(6): 1702-1708.
[9]	吴鹏清,曾令鹏,罗朝霞,雷洋洋,苟瑞琴,张庆. 分化型甲状腺癌患者术后行碘-131治疗致胸腺生理性摄取1例报告及文献复习[J]. 吉林大学学报(医学版), 2025, 51(5): 1358-1362.
[10]	李宏丽,王梦瑶,刘洋洋,张卉,李丽. KHSRP通过激活JAK/STAT信号通路对结直肠癌细胞生物学行为的影响[J]. 吉林大学学报(医学版), 2025, 51(4): 996-1006.
[11]	胡向锦,孙秀梅,陈楷,吴国民. 骨性Ⅱ类错颌畸形伴OSAHS患者双颌前移术后上气道变化1例报告及文献复习[J]. 吉林大学学报(医学版), 2025, 51(2): 493-500.
[12]	张琦,徐晓媛,吴聿淼,张晗,胡志强,袁佳敏,崔宇琛,朱宪春. 无托槽隐形矫治联合正颌手术治疗骨性Ⅱ类高角错牙合畸形患者1例报告及文献复习[J]. 吉林大学学报(医学版), 2025, 51(2): 508-515.
[13]	王璐瑶,赵晨曦,张婉泽,刘林林. 第二原发性气管腺样囊性癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2025, 51(1): 215-221.
[14]	张金萍,佟玲玲,高璐,程洪晶,盛敏佳. 腹壁寄生性平滑肌瘤并发播散性腹膜平滑肌瘤病1例报告及文献复习[J]. 吉林大学学报(医学版), 2024, 50(5): 1432-1437.
[15]	阮文青,付泽润,黄逸,李龙云,孙耀,李凯. 低血压预测指数在机器人辅助腹腔镜膀胱切除术患者血流动力学管理中应用1例报告及文献复习[J]. 吉林大学学报(医学版), 2024, 50(4): 1130-1136.

贝伐珠单抗联合FOLFIRI方案治疗晚期直肠癌并发直肠阴道瘘1例报告及文献复习

Treatment of advanced rectal cancer with rectovaginal fistula through bevacizumab combined with FOLFIRI regimen: A case report and literature review

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 23

相关文章 15

Metrics

本文评价

推荐阅读 10